BURNABY, B.C. — LifeLabs union members are urging the B.C. government to review the company’s ownership, one day after ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Following B.C. Premier David Eby’s beefed up made-in-Canada policy announcement on Thursday, a day later, LifeLabs union ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

The comedian Drew Lausch relayed a story about his recent hookup with a doctor (OK brag) and what the experience taught him ...

About 1,200 B.C. LifeLabs employees have been on rotating strikes since Feb. 16. On Monday, four of 10 locations in or near ...

Quest Diagnostics Inc. closed 8.28% below its 52-week high of $178.87, which the company reached on March 10th.

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter, the ...

The stock is down 9.9% since the results and currently trades at $225.11. Processing approximately one-third of the adult U.S. population's lab tests annually, Quest Diagnostics (NYSE:DGX) provides ...

Quest Diagnostics (DGX) launched a new laboratory blood test designed to help physicians confirm amyloid brain pathology due to Alzheimer’s ...